Leukapheresis Market size is anticipated to reach USD 8 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of leukapheresis was USD 1 Billion. The demand for leukapheresis is driven by an increasing incidence of leukemia, as leukapheresis is a critical medical procedure to trealeukemia. As per a report, in 2023, there will be 1,958,310 new cancer cases diagnosed in the US; of these, leukemia, lymphoma, and myeloma cases are predicted to make up 9.4%. Leukapheresis is a procedure to remove white blood cells that may be used for other medical purposes, such as stem cell transplantation and immunotherapy. The need for leukapheresis to support these treatments is increasing as the incidence of leukemia increases, and this has led to an increase in sales.
Leukapheresis can be performed to harvest stem cells from children for other cancer patients as well as to treat or eliminate excess WBCs in children with lymphoma. Leukapheresis is a market focus because of its potential and advantages in this application, particularly as children's leukapheresis treatment is now only available in a small number of hospitals in developed and developing nations. Therefore, this factor is propelling the growth of the leukapheresis market.
Growth Drivers
Challenges
Base Year |
2023 |
Forecast Year |
2024-2036 |
CAGR |
~ 6% |
Base Year Market Size (2023) |
~ USD 1 Billion |
Forecast Year Market Size (2036) |
~ USD 8 Billion |
Regional Scope |
|
Product Type (Leukapheresis Columns & Cell Separators, Leukapheresis Disposables, Apheresis Devices, Leukoreduction Filters)
Leukapheresis disposables segment in the leukapheresis market is expected to hold a share of 46% during the forecast period. The demand for leukapheresis disposables is also increasing due to the increasing incidence of diseases such as leukemia, lymphoma, and autoimmune diseases. For instance, some of the more than 80 distinct autoimmune illnesses that impact about 4% of the global population are type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, Crohn's disease, psoriasis, and scleroderma. The disposables used in leukapheresis operations include items for entering blood vessels, storing blood components, and preventing blood clotting with anticoagulants. Both therapeutic leukapheresis and automated blood collection employ disposables. They consist of a variety of solutions such as saline, anticoagulants, media, columns, filters, and cell separation kits, as well as apheresis catheters, needle sets, centrifuge bowls, tubing sets/pipeline systems, and collection bags. In addition, due to their convenience, cost-effectiveness, and reduced risk of cross-contamination, there is a growing trend toward the adoption of single-use technologies in healthcare settings. Therefore, the growth of this segment is being driven by these factors.
Application (Therapeutic, Research)
Therapeutic segment in the leukapheresis market is anticipated to hold the largest share of 54% during the forecast period. Leukapheresis, including leukemia, lymphoma, and myeloma, is a key therapeutic intervention for the management of many blood disorders. In addition, leukapheresis is an integral part of stem cell transplantation, which is a cure for certain hematologic malignancies and genetic disorders. In addition, leukapheresis helps to reduce excessive immune responses, reduce inflammation, and reduce symptoms of the disease by removing pathogenic immune cells or inflammatory mediators from circulation. In addition, new therapeutic solutions for leukapheresis beyond traditional indications are being explored in ongoing research and clinical studies. These include leukapheresis for the treatment of sepsis, acute respiratory distress syndrome, and some neurological disorders. Therefore, these factors are contributing to the growth of therapeutic segment.
Our in-depth analysis of the global market includes the following segments:
Product Type |
|
Application |
|
End-user |
|
North American Market Forecast
North American leukapheresis market is poised to hold the largest share of 36% during the forecast period. The primary drivers of the current leukapheresis industry are an increase in neurological illnesses and blood-related disorders like "leukemia," which are already extremely frequent and common in this region. Additionally, the region is home to highly qualified medical personnel and well-equipped facilities. Furthermore, the region sets the standard for the use of cell-based treatments including stem cells and CAR T-cell therapy. For instance, in December 2021, T-ChargeTM, Novartis's next-generation CAR-T platform, was unveiled. It will act as the basis for several novel investigational CAR-T cell therapies that the company has in the works. The leukapheresis market expanded as a result of the region's increasing need for cell-based therapies.
European Market Statistics
Leukapheresis market in Europe is expected to grow with a share of 28% by the end of 2036. The rising incidence of blood disorders is one of the key factors expanding the market in the region. Also, the growth can be attributed to the growing investment in the healthcare sector. For instance, 2018 saw USD 1.95 billion financed by Europe in research and innovation through 1.708 initiatives in 20 Member States. The top three countries with the largest financing shares are Spain, Hungary, and Poland. Furthermore, Europe is a center for immunotherapy, cancer, and hematology clinical research and innovation. Leading academic institutions and pharmaceutical businesses are present, which promotes innovation and expands the leukapheresis market.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?